{"id":"W2790250024","doi":"10.1158/1538-7445.sabcs17-ot3-05-04","title":"Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palbociclib; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Population; Discontinuation; Chemotherapy; Randomization; Hazard ratio; Cancer; Randomized controlled trial; Progression-free survival; Surgery; Confidence interval","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001656663,0.0007900022,0.001821478,0.000807568,0.0003292164,0.0001640171,0.0003836674,0.00007165768,0.0008813775],"category_scores_gemma":[0.000117774,0.0005640833,0.0001169778,0.001698574,0.0007255886,0.0004506939,0.0001230836,0.0006425485,0.00001793533],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01052722,"about_ca_system_score_gemma":0.002658668,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.04156261,"about_ca_topic_score_gemma":0.05541593,"domain_scores_codex":[0.9932458,0.001369774,0.001018909,0.00138559,0.001398099,0.001581817],"domain_scores_gemma":[0.9962559,0.001121552,0.0004250602,0.0006975982,0.001093786,0.0004060516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7348509,0.02221044,0.02681972,0.00007535244,0.001949525,0.000219958,0.007036232,0.0004123199,0.002083794,0.000002810839,0.00002605226,0.2043129],"study_design_scores_gemma":[0.9078152,0.02189185,0.05996639,0.001284973,0.0002531805,0.000003976589,0.003333905,0.002455591,0.002409525,0.00001022886,0.00005205732,0.000523195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824352,0.000691628,0.00002847399,0.0009520141,0.0001180558,0.01465978,0.0008464623,0.00005717206,0.0002111797],"genre_scores_gemma":[0.9856343,0.0005017046,0.002122497,0.00009629767,0.0002265782,0.01062089,0.0001428708,0.0001778202,0.0004770047],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2037897,"threshold_uncertainty_score":0.9996811,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1539898728747608,"score_gpt":0.4970297648779379,"score_spread":0.3430398920031771,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}